Current Hematologic Malignancy Reports

, Volume 1, Issue 2, pp 75–80

The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective

Authors

    • Dana Farber Cancer Institute
  • D. Gary Gilliland
Article

DOI: 10.1007/s11899-006-0026-3

Cite this article as:
Wadleigh, M. & Gilliland, D.G. Curr Hematol Malig Rep (2006) 1: 75. doi:10.1007/s11899-006-0026-3

Abstract

A common somatic point mutation has recently been identified in the Janus kinase 2 (JAK2) gene in virtually all cases of polycythemia vera and in a majority of patients with essential thrombocythemia and idiopathic myelofibrosis. This common mutation in the pseudokinase autoinhibitory domain of the enzyme results in constitutive tyrosine kinase activation, which in turn leads to cytokine hypersensitivity and factor independence in factor-dependent cell lines, and causes polycythemia in mice. This discovery has led to greater understanding of the molecular pathogenesis of the chronic myeloproliferative disorders, which may translate into targeted therapy.

Download to read the full article text

Copyright information

© Current Science Inc 2006